The effects of pioglitazone treatment in lipidemic profile and elastographic indices in non-diabetic patients with nash

Background and Aims: Non-Alcoholic Steatohepatitis (NASH) is becoming the most frequent cause of chronic liver disease and is an emerging cardiovascular risk factor. However, the treatment of NASH remains largely empirical with pioglitazone being probably the most effective agent. We aimed to evaluate the effects of pioglitazone on lipid profile in patients with NASH without concurrent type 2 diabetes mellitus (T2DM).